Clinical Trial Update: Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity results for JNJ-64041809, a live attenuated Listeria-based immunotherapy, in metastatic castration-resistant prostate cancer w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• JNJ-64041809 (Listeria monocytogenes-based live attenuated immunotherapy)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 1 | Status: COMPLETED